| http://www.w3.org/ns/prov#value | - SBP was assumed to be less important.1 It is not therefore surprising that, in all studies on the prevention of morbidity and mortality by antihypertensive treatment carried out during these years, efficacy should have been evaluated by changes in DBP and that regulatory agencies such as the Food and Drug Administration or the European Medicines Agency use this type of design to the present day.
|
